NCT05601830 is a Phase 1 clinical trial of QN-030a in Minimal Residual Disease, sponsored by Institute of Hematology & Blood Diseases Hospital, China.

Who is sponsoring NCT05601830?

NCT05601830 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT05601830?

Interventions in NCT05601830: QN-030a, Cyclophosphamid, Fludarabine, Cytarabine.

What condition does NCT05601830 study?

NCT05601830 studies Minimal Residual Disease.

Is NCT05601830 still recruiting?

NCT05601830 is currently terminated. Last updated 6 November 2024.

Last reviewed 2024-11-06 · How we verify

NCT05601830

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Terminated Phase 1 Last updated 6 November 2024

What this trial tests

Phase 1 trial testing QN-030a in Minimal Residual Disease in 1 participant. Terminated before completion.

Timeline

9 October 2022

Primary endpoint
30 June 2023

30 June 2023

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	9 October 2022
Primary completion	30 June 2023
Estimated completion	30 June 2023
Sites	1 location across China

Drugs / interventions tested

QN-030a — full drug profile →
Cyclophosphamid — full drug profile →
Fludarabine (FLUDARABINE) — full drug profile →
Cytarabine — full drug profile →

Conditions studied

Minimal Residual Disease — all drugs for Minimal Residual Disease →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

18 and older, any sex, with Minimal Residual Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in Acute Myeloid Leukemia Minimal Residual Disease(AML MRD). This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-020a in patients with AML MRD, where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Beyond αβ T cells: NK, iNKT, and γδT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML.
Kent A, Crump LS, Davila E. · · 2023 · cited 21× · PMID 37654497 · DOI 10.3389/fimmu.2023.1202950
NK cell-based immunotherapy strategies for myeloid leukemia.
Zhang L, Zhao Y, Dong Y, Jiang X. · · 2025 · cited 4× · PMID 40726987 · DOI 10.3389/fimmu.2025.1621885

Verify or expand the search:

Other trials of QN-030a

Trials testing the same drug.

NCT05665114 — Natural Killer(NK) Cell Therapy in r/r AML · Phase 1 · unknown

Other recruiting trials for Minimal Residual Disease

Currently open trials in the same condition.

NCT07136077 — A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Co · Phase 2 · recruiting
NCT07291921 — To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and · recruiting
NCT06930807 — Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer · NA · recruiting
NCT06358430 — Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination · Phase 1 · recruiting
NCT06536959 — VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS · Phase 2 · recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05601830 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 6 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05601830.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing